💊 Medicamentos A-Z 🧬 Alvos 🛠 Ferramentas 📚 Guias
Todos os Medicamentos Classes de Medicamentos Áreas Terapêuticas Efeitos Colaterais
Guias Glossário Linha do Tempo
Comparações Percursos de Medicamentos Famílias de Medicamentos
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Mitapivat

CHEMBL4299940 Phase 4 Aprovado Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
450.6 g/mol
LogP
1.8
Phase
4

This oral activator of the red blood cell enzyme pyruvate kinase (PKR) is used to treat hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited condition where red blood cells break down prematurely. By restoring PKR activity, it helps red blood cells survive longer and improves anemia.

Peso Molecular

450,6000 g/mol

LogP

1,80

TPSA

91,00 Ų

Regra dos 5 de Lipinski

Aprovado

Mecanismo de Ação

Absorbs, reflects, or scatters ultraviolet radiation before it reaches the skin, protecting against UV-induced DNA damage and sunburn.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Absorbs, reflects, or scatters ultraviolet radiation before it reaches the skin, protecting against UV-induced DNA damage and sunburn.

Estrutura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=C(c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1)N1CCN(CC2CC2)CC1

                

                

                
                

                    
InChI

                    
InChI=1S/C24H26N4O3S/c29-24(28-15-13-27(14-16-28)17-18-6-7-18)20-8-10-21(11-9-20)26-32(30,31)22-5-1-3-19-4-2-12-25-23(19)22/h1-5,8-12,18,26H,6-7,13-17H2

                

                

                

                    
                    

                        
Molecular Formula

                        
C24H26N4O3S

                    

                    
                    

                        
HBD / HBA

                        
1 / 6

                    

                    
                    

                        
Ligações Rotacionáveis

                        
6

                    

                    
                    
                    

                        
Átomos Pesados

                        
32

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Perguntas frequentes

                

                    
                    

                        
                        

                            
This oral activator of the red blood cell enzyme pyruvate kinase (PKR) is used to treat hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited condition where red blood cells break down prematurely. By restoring PKR activity, it helps red blood cells survive longer and improves anemia.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Absorbs, reflects, or scatters ultraviolet radiation before it reaches the skin, protecting against UV-induced DNA damage and sunburn.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Mitapivat is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL4299940.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 59634741.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Aviso Médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.